Hatte die Kauforder heute morgen schon eingegeben und dann doch nicht zugeschlagen. Ärgerlich... Kann allerdings keine News finden außer dem Typ bei Marketwatch der schreibt, er hätte schon die Impfung von Novavax erhalten... https://www.marketwatch.com/story/...the-novavax-underdog-11606393298
Vom 25.11.2020 Novavax announced that it will participate in two upcoming investor conferences. Novavax COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference.
+ pro Tag tanzt für Euch alle jetzt jeweils ein Luigi ein Freudentänzchen:
____________________________
----------- So wie einem das Licht nicht ohne die Dunkelheit bewusst würde, so gibt es keine Situation, in der nicht etwas POSITIVES zu entdecken wäre.
dieser Satz " Daten für Impfstoffkandidaten von Johnson & Johnson und Novavax Inc. werden in den kommenden Monaten erwartet. " wie lange wird es denn nun noch dauern , da ist ja Biontech und Pfizer schon stark am Produzieren nicht so gut für unsere Aktie
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Analysis of safety and immunogenicity of the Novavax SARS-CoV-2-3Q-2P-FL immunogen in mice and baboons revealed strong B and T cell responses to the vaccine with no evidence of vaccine-associated enhanced respiratory disease (15). Phase 1 and 2 clinical trial results showed that the vaccine induced immune responses exceeding levels seen in COVID-19 patients (31). Overall, we found that NVAX-CoV2372 is stable, homogeneous, and locked in the antigenically preferred prefusion conformation. With structural, biophysical, and antigenic characterization now complete, ongoing evaluation in humans will provide the true proof-of-principle for this vaccine concept.
...Data shows that the key vaccine India is banking on is Novavax. The country has managed the maximum dose of Novavax vaccine (One billion doses) while dealing with Oxford-AstraZeneca for half a billion.
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
...the key features of these antibodies are their ability to neutralize virus, and they have been shown to be highly protective in multiple studies using multiple constructs.
... Taken together, our findings indicate that the adjuvanted, recombinant, full-length spike protein nanoparticle vaccine NVX-CoV2373 is a promising candidate that warrants testing in efficacy studies. Phase 2 has commenced on the basis of the safety results of the day 35 primary analysis, and phase 3 is in preparatory stages.
The world's largest vaccine producer will manufacture AstraZeneca Plc's Covishield and another formulation developed by U.S. rival Novavax Inc . Organizations such the GAVI vaccine group and the Bill & Melinda Gates Foundation are backing both candidates for large-scale distribution around the globe.
habe gerade ein gutes Video zum Thema Impfstoff Gewinner, abseits von den Impfstoffherstellern gefunden. Vielleicht für wen interessant... Anbei der Link: https://www.youtube.com/watch?v=OYf7hyeHvU4
Thread abonnieren
